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Abstract
The importance of bioconjugates within the field of chemistry drives the need for novel 
methodologies for their preparation. Well-defined and stable bioconjugates are easily accessible 
via the utilization of unnatural amino acids (UAAs). As such, we have synthesized and 
incorporated two new UAAs into green fluorescent protein, and optimized a novel Cadiot–
Chodkiewicz bioconjugation, effectively expanding the toolbox of chemical reactions that can be 
employed in the preparation of bioconjugates.
Bioconjugates represent a class of molecules in which a bio-macromolecule is linked to 
another molecule, typically a probe, a surface, or a cytotoxic compound.1,2 Protein-based 
bioconjugates, in which a protein is the biomolecule, represent an ever-expanding field of 
research. Specifically, protein-based bioconjugates are becoming increasingly popular for 
‘‘lab-on-a-chip’’ technologies, in which a diagnostic protein is immobilized on a surface, as 
well as towards the development of novel cancer therapeutics via the preparation of 
antibody-drug conjugates.3–5
The methods to generate a bioconjugate range from non-covalent interactions, typically 
adsorption and encapsulation, to covalent linkages.6 While a covalent attachment is more 
robust, and less easily disrupted in a biological setting, obtaining a degree of specificity 
during the synthesis has precluded its widespread application. This is a consequence of often 
utilizing reactive residues within the protein of interest. However, there are typically 
multiple nucleophilic residues that can react within the protein.1 The result is a non-specific 
coupling that can either disrupt normal protein function, result in improper orientation of the 
protein-bioconjugate, or lead to heterogeneous mixtures of linkages at multiple residues.6 
These limitations can be overcome by site-specifically incorporating UAAs with chemical 
functionalities not found in the canonical amino acids.7,8 In particular, the suppression of the 
amber (TAG) stop codon via an exogenous amino-acyl tRNA synthetase (aaRS)/tRNA pair 
allows a high level of control over the position of the UAA.9 These UAA-containing proteins 
can then be conjugated to other molecules via a bioorthogonal reaction that occurs at 
physiological conditions (pH = 7, 37 °C) with no chance of cross-reaction with other 
biomolecules.10,11
†Electronic supplementary information (ESI) available: Experimental protocols, bioconjugation optimization and SDS-PAGE analysis. 
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Indeed a variety of bioorthogonal reactions have already been developed. These include the 
copper(I)-catalyzed cycloaddition between azides and terminal alkynes,12–14 the strain-
promoted cycloaddition,15–17 the oxime formation,18–21 and more recently, the formation of 
a conjugated diyne via the copper(I)-catalyzed Glaser–Hay coupling.22 Despite the wide 
array of bioorthogonal chemistries available, each possessing advantages and disadvantages, 
the individual requirements of the bioconjugate help dictate which reaction may be best to 
employ. Due to the increasing application of bioconjugates, the development of novel 
bioorthogonal reactions (and UAAs with which they can be employed) are at the forefront of 
the field.
The Cadiot–Chodkiewicz reaction affords a conjugated diyne via the reaction of a terminal 
alkyne and a halo-alkyne (Fig. 1). In the presence of a copper(I) salt and a monodentate 
nitrogenous ligand, usually triethylamine (TEA), the reaction proceeds to form a covalent 
linkage in the form of a conjugated diyne in a relatively chemo-selective fashion.23,24 
Furthermore, the overall reaction is net redox neutral, as a single copper(I) catalyst goes 
through a series of oxidative additions and reductive eliminations with the bromo-alkyne and 
terminal alkyne reactant to yield the conjugated diyne.25
The Cadiot–Chodkiewicz reaction has diverse applications to many areas of chemistry. It has 
been utilized in polymerization reactions, such as in the formation of the backbone of a 
solid-state polymer crystal, or in the fabrication of polymerized monolayer assemblies.26,27 
Additionally, several acetylenic natural products exhibiting valuable biological properties 
can be obtained via a Cadiot–Chodkiewicz reaction.28
Similar to the Cadiot–Chodkiewicz reaction, the Glaser–Hay coupling of two terminal 
alkynes also affords a diyne.29,30 The reaction brings together two terminal alkynes generate 
a diyne linkage; however, it is not redox neutral and has chemoselectivity issues as nothing 
differentiates the two terminal alkynes.31 The reaction involves the addition of a bidentate 
nitrogenous ligand, triethylmethylenediamine (TMEDA),32 which lowers the reaction 
temperatures and enhances the kinetics of the reaction. Recently, we demonstrated a 
bioorthogonal variant of the Glaser–Hay reaction that can be conducted in an aqueous 
setting under physiological conditions.22 Using a terminal alkyne-containing UAA, we were 
able to demonstrate that the reaction proceeds to completion within approximately 6 h at 
4 °C, with near quantitative conjugation. As previously mentioned, the Glaser–Hay coupling 
of terminal alkynes has a chemoselectivity issue when the terminal alkynes differ, resulting 
in the formation of unwanted homodimers. However, due to the steric bulk of the protein, we 
found that the homodimerization of the reaction was mostly inhibited, leading to primarily 
the desired protein heterodimer product. As such we were able to demonstrate that the 
Glaser–Hay reaction could be employed as a novel bioorthogonal chemistry, yielding stable 
conjugates with well-defined geometries. However, the reaction was limited by the oxidative 
damage of the protein due to the mechanistic cycling of the copper through three different 
redox states. As a result, reactions proceeding for longer than 6 h, resulted in oxidative 
damage and protein degradation.
A key component of the Glaser–Hay mechanism is the formation of a copper(II)-hydroxyl 
intermediate, which has been shown to produce hydroxyl radicals that are deleterious to 
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living systems.33 Because the copper(I) of the Cadiot–Chodkiewicz reaction is not thought 
to utilize copper(II) intermediates, we reasoned that the chemistry could be employed in a 
biological context to minimize previously observed oxidative damage. Furthermore, the 
reaction is highly chemoselective, as the use of a halo-alkyne minimizes the formation of 
homodimer side products by differentiating the two alkynes. Ultimately, this has the 
potential to increase the yield of the conjugated protein product. Based on these facts and the 
limitations of the bioorthogonal Glaser–Hay, we sought to develop a bioorthogonal variant 
of the Cadiot–Chodkiewicz reaction that could be conducted in an aqueous setting and under 
physiological conditions.
In order to conduct and optimize a Cadiot–Chodkiewicz bioconjugation, new UAAs 
harboring a terminal haloalkyne needed to be synthesized and incorporated into a protein. In 
order to probe UAA-dependent effects on the reaction, aliphatic and aromatic brominated 
alkynyl UAAs were prepared from the previously reported protected p-
propargyloxyphenylalanine (pPrF, 1) and the p-ethynylphenylalanine (pEtF, 2) 
respectively.34,35 Gratifyingly, the well-established bromination of phenylacetylene using N-
bromosuccinamide (NBS) and silver nitrate worked well for the synthesis of both UAAs in 
moderate yields.36,37 Following deprotection, the final UAAs, p-bromo-
propargyloxyphenylalanine (pBrPrF, 3) and p-bromo-ethynylphenylalanine (pBrEtF, 4), 
were recovered in overall good yields (67% and 34% respectively) (Fig. 1).
With the pBrPrF and pBrEtF in hand, it was imperative to incorporate these UAAs into a 
model protein. Due to both its fluorescent properties and well-documented prior use in UAA 
development technologies, green fluorescent protein (GFP) was selected as a model system. 
Specifically, attempts were made to incorporate newly synthesized UAAs at residue 151 by 
suppressing the amber stop codon. Furthermore, our previous work immobilizing GFP 
revealed that this surface exposed site is ideal for UAA placement, as the rigidity of the 
residue helps orient the bioorthogonal functional handle.38 In lieu of undergoing a tedious 
aaRS selection process, we hoped to incorporate the brominated UAAs using the previously 
described promiscuous pCNF aaRS.39,40 The pCNF aaRS was investigated first to 
incorporate pBrPrF and pBrEtF due to their structural similarity to other UAAs that the 
pCNF aaRS incorporates.
BL21(DE3) E. coli were co-transformed with a pEVOL–pCNF plasmid and a pET-GFP-
TAG151 plasmid and used to initiate an expression culture at OD600 0.1 which was grown to 
an OD600 0.7. The culture was subsequently centrifuged and the cell pellet was resuspended 
in 4 mL of LB broth supplemented with antibiotics, IPTG, arabinose, and the presence or 
absence of a UAA.34 This previously reported expression protocol allowed for the 
minimization of the amount of UAA employed, and was found to be very effective. After 
18–20 h at 37 °C, cells were pelleted and the expressed GFP was purified.
Gratifyingly, the promiscuous pCNF aaRS incorporated both brominated-UAA variants with 
a higher fidelity than the simple terminal alkyne analogs (Fig. 2). As is to be expected, the 
smaller pBrEtF UAA, had a higher incorporation than the pBrPrF. We hypothesize that the 
1-bromo-alkyne moiety provides a degree of hydrophobic character to the UAA, making the 
Maza et al. Page 3
Chem Commun (Camb). Author manuscript; available in PMC 2017 June 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
interaction between the amino acid and the hydrophobic binding pocket of the aaRS more 
favourable.
With both brominated alkyne UAAs in hand, it was feasible to develop a bioorthogonal 
Cadiot–Chodkiewicz reaction. Initial studies employed the pBrPrF-containing GFP variant, 
to mimic previous Glaser–Hay pPrF-GFP studies and provide an effective comparison. The 
Cadiot–Chodkiewicz reaction was carried out in PBS (pH = 7) using copper iodide and 
triethylamine (TEA) (both at a final concentration of 5 mM) in the presence of a terminal 
alkyne-containing fluorophore (AlexaFluor 488 alkyne) at 4 °C for 6 h. The reaction was 
successful, as fluorescence could be detected on a denatured SDS-PAGE gel only when 
protein and fluorophore were exposed to the CuI/TEA system (Fig. 3). Even more exciting 
was the minimal protein degradation relative to the previously reported Glaser–Hay reaction. 
Also, due to the chemoselective nature of the reaction no protein dimerization was detected, 
and fluorophore dimerization was minimal and easily removed.
In an attempt to further optimize the reaction, both copper concentrations and temperatures 
were varied. A 5 mM working Cu(I) concentration was found to be ideal, which represents a 
marked improvement over the ~50 mM concentrations required for the Glaser–Hay reaction 
(see ESI†). Previous reports have indicated that in vivo use of copper-mediated 
bioorthogonal chemistries required working concentrations of near 0.1 mM of copper(I) salt 
to minimize cytotoxicity.10,41 Thus, the minimized copper concentrations help bring 
bioorthogonal conjugated diyne chemistry into the range of in vivo use. These copper 
concentrations also had no impact on GFP fluorescence as determined by control reactions. 
Additionally, the optimal temperature profile for the reaction was also investigated. After 
performing a time course of the reaction at both 37 ° C and 4 ° C, we were able to determine 
very little difference between either temperature at early time-points. However, as the 
reaction was extended to 24 h, greater protein degradation at 37 ° C occurred, most likely 
due to an increase in the rate of disproportionation of the Cu(I) catalyst at this temperature, 
producing a reactive copper(II) species (Fig. 3 and ESI†). However, for the 4 ° C 
temperature profile the reaction reached approximately 86% completion in 4 h with minimal 
protein degradation, indicating that the bioorthogonal Cadiot–Chodkiewicz reaction can be 
performed quickly and in a relatively mild conditions. Extended times and temperatures 
resulted in higher yields, however were accompanied by protein degradation.
We next sought to explore the effects of an aromatic variant of the pBrPrF. As such, pBrEtF-
GFP151 was expressed, and subjected to coupling conditions at 4 ° C in the presence of an 
alkyne fluorophore. Once again a successful conjugation was observed as determined by 
SDS-PAGE (see ESI†). Only samples exposed to the CuI/TEA system exhibited 
fluorescence while other controls did not, indicating the fluorescence was not due to non-
specific interactions. Interestingly, the use of an aromatic containing bromoalkyne appears to 
be less effective in the Cadiot–Chodkiewicz reaction than its aliphatic analog.
†Electronic supplementary information (ESI) available: Experimental protocols, bioconjugation optimization and SDS-PAGE analysis. 
See DOI: 10.1039/c5cc08287k
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Next we became interested in exploring how the novel biological Cadiot–Chodkiewicz 
conjugation compared to our previously described Glaser–Hay reactions. In direct 
comparison, the Cadiot–Chodkiewicz exhibited far less protein degradation as compared to 
the Glaser–Hay versions of either an aliphatic (pPrF) or aromatic (pEtF) terminal alkyne 
containing UAAs. Furthermore, the data indicates that the biological Cadiot–Chodkiewicz 
reaction proceeds at a faster rate than the Glaser–Hay, with the aliphatic version (pBrPrF) of 
the coupling reaching completion the fastest in 4 h (Fig. 4). Gratifyingly, these results 
correlate well with the mechanistic understanding of both reactions, as the Cadiot–
Chodkiewicz requires a single copper atom, while the Glaser–Hay necessitates two copper–
alkyne conjugates to form the diyne product. Moreover, the Cu(I)/(III) redox couple of the 
Cadiot–Chodkiewicz reaction most likely aids in the minimized protein oxidation relative to 
the Glaser–Hay coupling that involves a reactive Cu(II) intermediate. However, it is 
important to note that the Cadiot–Chodkiewicz requires brominated UAAs, requiring 
additional synthetic preparation. In comparison to other bioconjugation techniques, the 
Cadiot–Chodkiewicz reaction may be slower; however, it employs more synthetically 
accessible UAAs and results in a well-defined linear geometry primed for further reactions. 
Thus, the selection of the Cadiot–Chodkiewicz reaction may be dependent on the 
downstream application and available resources.
Overall, we have accomplished the successful application of the Cadiot–Chodkiewicz 
reaction to a biological context. Furthermore, we have demonstrated that the reaction can be 
performed with minimal protein oxidation. Finally, we have showed that the Cadiot–
Chodkiewicz variant requires less harsh copper(I) concentrations, bringing the reaction near 
the range for in vivo use. Future work will involve optimization of conditions to increase the 
compatibility of the reaction with biological systems, and extension of the reaction towards 
in vivo applications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Cadiot–Chodkiewicz reaction and associated UAAs. (A) Standard Cadiot–Chodkiewicz 
reaction employing a copper(I) salt to couple a terminal alkyne to a haloalkyne, affording an 
asymmetrical conjugated diyne product. (B) p-Propargyloxyphenylalanine (1, pPrF), p-
ethynylphenylalanine (2, pEtF), p-bromopropargyloxyphenylalanine (3, pBrPrF), p-
bromoethynylphenyl-alanine (4, pBrEtF) incorporated into GFP-151 for Glaser–Hay and 
Cadiot–Chodkiewicz reactions.
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Fig. 2. 
Expression of UAA-containing GFP151 using the promiscuous pCNF aaRS. (A) A stained 
SDS-PAGE gel indicated successful incorporation of 3 and 4 over background (−). A 
positive control, 1, was also utilized in an expression. (B) Data for overall incorporation of 
UAAs via the pCNF aaRS as measured via absorbance at 280 nm on a nanodrop 
spectrophotometer (ε/1000 = 20, MW = 26.80 kDa). Data obtained were normalized to the 
pPrF UAA (1) to demonstrate the difference in incorporation efficiency over the previously 
reported UAA.
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Fig. 3. 
Bioorthogonal Cadiot–Chodkiewicz reaction. (A) The reaction performed on GFP (0.2 mg 
mL−1) and AlexaFluor 488 (0.2 mM) in the presence of 5 mM of CuI and 5 mM TEA at 4 ° 
C. Fluorescence is only observed in the presence of the CuI/TEA system. (B) Reaction 
profile at 4 ° C over a 24 h time period. Following analysis via SDS-PAGE, fluorescent 
imaging, and staining with coomassie blue, protein levels were normalized to the 0 time 
point control. The protein levels indicate minimal to no protein degradation occurs, even at 
longer time points. Analysis of coupling efficiency was determined by calculating the ratio 
of fluorescence to coomassie staining for each time point. All reactions were performed in 
triplicate.
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Fig. 4. 
Comparison of alkyne reactions. Reactions were conducted either under the described 
Cadiot–Chodkiewicz conditions or the Glaser–Hay conditions at 4 ° C depending on 
incorporated UAA. Due to differences in protein levels resulting from oxidative damage, the 
ratio of fluorophore coupling for each data set was normalized to the 24 hour time point in 
order to compare coupling trends between reactions.
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